TL;DR
This study reveals a significant association between an elevated AST/ALT ratio and a higher risk of osteopenia or osteoporosis in patients with type 2 diabetes mellitus (T2DM). The AST/ALT ratio emerges as a promising, cost-effective biomarker for early detection and risk stratification of bone health issues in this vulnerable population.
What Problem Does This Paper Address?
Type 2 diabetes mellitus (T2DM) is a widespread chronic condition that significantly impacts bone health, increasing the risk of osteopenia and osteoporosis. These bone disorders, characterized by reduced bone mass and microstructural deterioration, lead to increased bone fragility and a higher susceptibility to fractures. The co-occurrence of T2DM and osteoporosis poses a substantial burden, escalating fracture risk, mortality, and socioeconomic costs. While T2DM is known to negatively affect bone metabolism through various pathways including hyperglycemia, hyperlipidemia, and vascular complications, identifying reliable and accessible biomarkers for early detection of bone health decline in T2DM patients remains a critical challenge. This paper investigates whether the AST/ALT ratio, a marker commonly used to assess liver function and inflammation, could serve as such a biomarker for osteopenia/osteoporosis in T2DM patients.
Methods
This study employed a cross-sectional design, retrospectively analyzing data from 589 T2DM patients aged 50-80 years. Patients were categorized into two groups based on their bone mineral density (BMD) T-score: a normal BMD group (T-score ≥ -1.0) and an osteopenia/osteoporosis (OP) group (T-score < -1.0). The association between the AST/ALT ratio and osteopenia/OP was examined using multivariate analyses. To assess the diagnostic performance of the AST/ALT ratio, receiver operating characteristic (ROC) curves were generated, and the area under the curve (AUC) was calculated. Participants were also divided into four quartiles based on their AST/ALT ratio to explore dose-response relationships.
Datasets
The study utilized data collected from patients hospitalized in the Department of Endocrinology at Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine between January 2022 and January 2024. The dataset included demographic information, health status, blood biomarkers (including AST, ALT, creatinine, BUN, HbA1c, fasting plasma glucose, 2h plasma glucose, total cholesterol, triglycerides, serum 25-hydroxy vitamin D, and serum osteocalcin), and BMD measurements. No new datasets were introduced.
Key Insights and Ideas
- Liver-Bone Axis Connection: The study reinforces the concept of a bidirectional relationship between liver and bone health, suggesting that metabolic dysfunction in the liver, as indicated by the AST/ALT ratio, can have downstream effects on bone metabolism.
- AST/ALT as a Proxy for Systemic Inflammation: Beyond just liver function, the AST/ALT ratio is posited to reflect systemic inflammation and oxidative stress, which are implicated in both metabolic syndrome and bone loss.
- Practical Biomarker Potential: The AST/ALT ratio is readily available from routine blood tests, making it a potentially cost-effective and practical tool for screening and monitoring bone health in T2DM patients, especially in resource-limited settings.
- Gradient of Risk: The study observed a clear trend where higher AST/ALT ratio quartiles were associated with a progressively higher prevalence of osteopenia/osteoporosis, indicating a dose-dependent relationship.
Key Results
- Patients with osteopenia/osteoporosis (T-score < -1.0) had significantly higher AST/ALT levels (1.17 ± 0.24) compared to those with normal BMD (T-score ≥ -1.0) (0.93 ± 0.16), with a P-value < 0.001.
- After adjusting for confounding factors, individuals in the third (Q3) and fourth (Q4) quartiles of the AST/ALT ratio had a significantly increased risk of osteopenia/osteoporosis compared to the lowest quartile (Q1). The adjusted odds ratios were 3.478 (95% CI 1.641–7.411) for Q3 and 15.278 (95% CI 6.377-36.837) for Q4.
- The AST/ALT ratio demonstrated good predictive ability for osteopenia/osteoporosis, with an AUC of 0.81 (95% CI 0.77-0.84). An optimal cut-off value of 0.968 was identified, suggesting that AST/ALT ratios above this threshold are associated with a higher risk.
- The AST/ALT ratio was negatively correlated with BMD at the femoral neck, left hip, and lumbar spine in the overall cohort.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size: While 589 patients were included, the authors suggest a larger cohort study is needed for validation.
- Cross-Sectional Design: This design prevents the establishment of causality and limits the ability to determine the temporal relationship between AST/ALT ratio and bone health. The possibility of reverse causality (e.g., bone health affecting AST/ALT) cannot be ruled out.
- Unclear Biological Mechanisms: The precise biological pathways linking the AST/ALT ratio to osteopenia/osteoporosis in T2DM patients require further investigation.
Future research should focus on longitudinal studies to establish causality and explore the underlying mechanisms, potentially involving inflammation, oxidative stress, and the liver-bone axis. Further validation in diverse populations is also recommended.
Summary updated